PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1197332
PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1197332
Contact us about how to customize the report with add-on data.
The intravenous solutions market is projected to record a CAGR of nearly 4.3% over the forecast period (2022-2027).
The intravenous solutions market was significantly impacted by the COVID-19 outbreak. With the sudden outbreak, the demand for IV solutions grew worldwide to provide essential nutrients to patients in the intensive care unit (ICU). COVID-19 positively impacted the studied market as most pharmaceutical, biotechnology, and research institutes have been focusing on developing IV-based treatments against COVID-19. Moreover, with the easing of lockdown restrictions and the introduction of vaccines, the research and development activities are accelerating, thus boosting the market's growth. The World Health Organization report in March 2020 suggested using conservative fluid management in patients with SARS COVID-19 when there is no evidence of shock. Several clinical studies are ongoing for different intravenous drug solutions to treat COVID-19 patients. For instance, clinicaltrial.gov conducted a study in 2020 titled "Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients (INVENT COVID)", by performing a randomized, double-blind, parallel-group, placebo-controlled, multi-center clinical study of intravenous imatinib in 90 mechanically-ventilated, adult subjects with COVID-19-related ARDS. This study is expected to be completed in 2022.
The major factor attributing to the market's growth is the increase in the prevalence of diseases, such as gastrointestinal diseases, neurological diseases, and cancer, where intravenous solutions are the main sources of energy for patients. According to the World Health Organization, diarrhea is the second leading cause of death in children under five years, with 370,000 deaths in 2019.
Product innovations, such as premixed solutions for better convenience and to reduce the amount of packaging waste, and the availability of solutions in portable packages, which becomes easier for the patients to use the drips in the comfort of their home rather than at a hospital, are few other factors boosting the market's growth. For instance, in June 2019, Eurolife Healthcare, a manufacturing and distribution company of specialty infusion and pharmaceuticals, launched intravenous IV products Discport and Lifeport, which reduce the chances of any infections and are easy to use.
However, regulatory and quality requirements contribute additional cost and complexity to the market. Intravenous fluids are regulated as pharmaceutical products and carry all the capital investment requirements of sterile injectable medications despite being sold at relatively low prices, hindering the market's growth.
Total parenteral nutrition is a method of administering nutritional fluids into the body through the digestive system and directly into the vein. These are majorly based on age, weight, height, and type of disease.
These are usually used for gastrointestinal anomalies, bowel syndrome, burns or injuries, chemotherapy, or other surgeries. According to the World Health Organization 2021, chronic diseases have always been a massive global challenge. They account for approximately 71% of all deaths worldwide. This trend is expected to affect the emerging countries the most, as the increasing lifestyle-based diseases and other risk factors are anticipated to be the most significant in developing areas. Thus, the rising prevalence of chronic diseases is expected to increase the demand for the total parenteral nutrition solution.
Cancer treatment includes localized therapies, such as surgery, radiation therapy, cryotherapy, heat or chemical ablation, and systemic therapies. Post-surgery, intravenous solutions become an essential aid in maintaining the fluids in the body.
Furthermore, as per the data of the Gastrointestinal Society, in December 2020, around 13-20% of the people in Canada developed irritable bowel syndrome. In such cases, total parenteral nutrition therapy was observed as primary adjunctive therapy in various medical conditions.
For instance, as per the GLOBOCAN 2020, the estimated number of new brain or nervous system cancer cases in the United States was 24,500 in 2020, and it is expected to reach 30,200 by 2040. This factor is expected to increase the supply of IV solutions to hospitals and clinics as the increasing prevalence of such cancer cases increases the number of hospital admissions.
Hence, with the higher prevalence of these diseases, proper management of fluids in the body becomes a crucial part, which is expected to positively impact the segment's growth.
The United States is expected to be a dominant country contributing to the market's growth during the forecast period (2022-2027). The major factors attributable to this growth are the rising burden of diseases, the rising number of preterm births, and the increasing number of surgeries.
For instance, according to the Centers for Disease Control and Prevention, cancer is the second leading cause of death among Americans. About one in four deaths in the United States is due to cancer. As per the American Cancer Society report, in 2020, there were around 1,806,590 new cases of cancer and 606,520 deaths in the United States.
Moreover, the rate of premature babies born in the United States is higher compared to other developed countries. According to an article published in November 2021, by the Centers for Disease Control and Prevention, in 2020, preterm birth affected 1 in every 10 infants born in the United States. As per the Centers for Disease Control and Prevention data, every six out of 10 adults suffer from some other chronic diseases.
In addition, the geriatric population is more prone to chronic diseases due to weak immune systems. According to the World Ageing Report 2019, the United States had 53,340 million people aged 65 years and above in 2019, and this number is expected to reach 84,813 million by 2050. This expected increase in the elderly population may increase the incidence rate of chronic diseases in the country, thus driving the use of intravenous solutions in their diagnosis and boosting the market.Additionally, the increasing burden of chronic diseases is creating tremendous opportunities for market players. The major market players are focusing on R&D activities to launch new and reliable treatments in the market, which is boosting the market's growth. Hence, the growing burden of chronic diseases and initiatives by market players are expected to boost the growth of the market during the forecast period.
The intravenous solutions market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Ajinomoto, B. Braun Melsungen AG, Baxter International, Grifols, and ICU Medical Inc.